drugset / Trial / NCT04841538
A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, RP2D and PK/pharmacodynamic profile of ES101 monotherapy in patients with advanced NSCLC and to further evaluate the antitumor efficacy of ES101 in advanced malignant thoracic tumors, including NSCLC and SCLC.
Timeline
- Start
- 2021-07
- Primary completion
- 2023-12
- Completion
- 2024-05
Outcome
Outcome not reported
Stopped (Business): “Sponsor's clinical development strategy adjustment”